Concord Biotech (CONCORDBIO)

FairStock Score: 95/100 — HIGH CONVICTION

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Concord Biotech as a Buffett-style business first: it earns high returns on capital, with ROCE 28.35% and ROE 17.39%, and carries no debt—Debt/Equity 0.00. That is a clean balance sheet. Growth is impressive: sales up 25.70%, profit up 43.76%, a five-year revenue CAGR of 18.57%, latest quarter sales ₹278 Cr and net profit ₹68 Cr. Free cash flow of ₹85 Cr is positive, and Piotroski F-Score 7/9 plus Altman Z-Score 5.93 suggest financial strength. The promoter holds 44.08%, which aligns interests. So the business quality is real. But Graham's question is price. At ₹1,451.30 and market cap ₹15,183 Cr, we pay P/E 49.99, P/B 7.53, EV/EBITDA 25.19, against book value ₹192.81. The Graham Number is ₹804.38, implying a margin of safety of -51.74%; I am paying nearly double the defensive value. The DCF intrinsic value of ₹53.58 is far below market, so I must ask whether growth can bridge that gap. Dividend yield is only 0.52%, giving little while I wait. FairStock Score 95/100 may flag high conviction, but score is not a margin of safety. I would call this a Fast Grower with excellent financial health. My move: watchlist, not buy at this price. I want a wider discount or clear evidence that high growth persists before I pay such a premium. The business passes my quality test, but the stock fails my price test.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer